Autor(es):
Fuchs, Flávio D. ; Fuchs, Sandra C. ; Moreira, Leila B. ; Gus, Miguel ; Nóbrega, Antônio C. ; Poli-de-Figueiredo, Carlos E. ; Mion, Décio ; Bortoloto, Luiz ; Consolim-Colombo, Fernanda ; Nobre, Fernando ; Coelho, Eduardo B. ; Vilela-Martin, José F. ; Moreno Jr, Heitor ; Cesarino, Evandro J. ; Franco, Roberto [UNESP] ; Brandão, Andréa A. ; de Sousa, Marcos R. ; Ribeiro, Antônio L.P. ; Jardim, Paulo C. ; Neto, Abrahão A. ; Scala, Luiz C.N. ; Mota, Marco ; Chaves, Hilton ; Alves, João G. ; Filho, Dario C.S. ; Pereira e Silva, Ricardo ; Neto, José A.F. ; Irigoyen, Maria C. ; Castro, Iran ; Steffens, André A. ; Schlatter, Rosane ; de Mello, Renato B. ; Mosele, Francisca ; Ghizzoni, Flávia ; Berwanger, Otávio
Data: 2014
Identificador Persistente: http://hdl.handle.net/11449/72338
Origem: Oasisbr
Assunto(s): amiloride; beta adrenergic receptor blocking agent; chlortalidone; dipeptidyl carboxypeptidase inhibitor; diuretic agent; hydrochlorothiazide; atherosclerosis; blood pressure measurement; cardiovascular risk; clinical protocol; cost effectiveness analysis; diabetes mellitus; double blind procedure; drug efficacy; drug safety; heart infarction; heart left ventricle hypertrophy; hypertension; hypokalemia; insulin resistance; ischemic heart disease; low drug dose; microalbuminuria; obesity; outcome assessment; prehypertension; randomized controlled trial; sodium restriction; sudden death; vascular disease
Descrição
Submitted by Vitor Silverio Rodrigues (vitorsrodrigues@reitoria.unesp.br) on 2014-05-27T11:25:30Z No. of bitstreams: 0Bitstream added on 2014-05-27T14:31:08Z : No. of bitstreams: 1 2-s2.0-79952197520.pdf: 336059 bytes, checksum: 6887bfb6c66c449f86ed80f9d7459718 (MD5)
Made available in DSpace on 2014-05-27T11:25:30Z (GMT). No. of bitstreams: 0 Previous issue date: 2011-03-05
Background: Blood pressure (BP) within pre-hypertensive levels confers higher cardiovascular risk and is an intermediate stage for full hypertension, which develops in an annual rate of 7 out of 100 individuals with 40 to 50 years of age. Non-drug interventions to prevent hypertension have had low effectiveness. In individuals with previous cardiovascular disease or diabetes, the use of BP-lowering agents reduces the incidence of major cardiovascular events. In the absence of higher baseline risk, the use of BP agents reduces the incidence of hypertension. The PREVER-prevention trial aims to investigate the efficacy, safety and feasibility of a population-based intervention to prevent the incidence of hypertension and the development of target-organ damage.Methods: This is a randomized, double-blind, placebo-controlled clinical trial, with participants aged 30 to 70 years, with pre-hypertension. The trial arms will be chlorthalidone 12.5 mg plus amiloride 2.5 mg or identical placebo. The primary outcomes will be the incidence of hypertension, adverse events and development or worsening of microalbuminuria and of left ventricular hypertrophy in the EKG. The secondary outcomes will be fatal or non-fatal cardiovascular events: myocardial infarction, stroke, heart failure, evidence of new sub-clinical atherosclerosis, and sudden death. The study will last 18 months. The sample size was calculated on the basis of an incidence of hypertension of 14% in the control group, a size effect of 40%, power of 85% and P alpha of 5%, resulting in 625 participants per group. The project was approved by the Ethics committee of each participating institution.Discussion: The early use of blood pressure-lowering drugs, particularly diuretics, which act on the main mechanism of blood pressure rising with age, may prevent cardiovascular events and the incidence of hypertension in individuals with hypertension. If this intervention shows to be effective and safe in a population-based perspective, it could be the basis for an innovative public health program to prevent hypertension in Brazil.Trial Registration: Clinical Trials NCT00970931. © 2011 Fuchs et al; licensee BioMed Central Ltd.
Hospital de Clínicas de Porto Alegre Universidade Federal do Rio Grande do Sul, Porto Alegre
Hospital Universitário Antônio Pedro Universidade Federal Fluminense, Niterói
Hospital São Lucas Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre
Hospital das Clinicas Universidade de São Paulo, São Paulo
Instituto do Coração Universidade de São Paulo, São Paulo
Faculdade de Medicina de Ribeirão Preto Universidade de São Paulo, Ribeirão Preto
Faculdade de Medicina São José do Rio Preto, São José do Rio Preto
Faculdade de Ciências Médicas Universidade de Campinas, Campinas
Faculdade de Ciências Farmacêuticas Universidade de São Paulo, Ribeirão Preto
Faculdade de Medicina de Botucatu Universidade Estadual de São Paulo, Botucatu
Universidade do Estado do Rio de Janeiro, Rio de Janeiro
Hospital das Clínicas Universidade Federal de Minas Gerais, Belo Horizonte
Hospital das Clínicas de Goiânia Universidade Federal de Goiás, Goiânia
Anis Rassi Hospital, Goiânia
Hospital Universitário Júlio Muller Universidade Federal de Mato Grosso, Cuiabá
Faculdade de Medicina Universidade de Ciências da Saúde Alagoas, Maceió
Faculdade de Medicina Universidade Federal de Pernambuco, Recife
Instituto de Medicina Integral Prof Fernando Figueira, Recife
Hospital Universitário Oswaldo Cruz/PROCAPE Universidade de Pernambuco, Recife
Hospital Universitário Valter Cantídio Universidade Federal do Ceará, Fortaleza
Hospital Universitário Universidade Federal Maranhão, São Luiz
Instituto de Cardiologia Fundação Universitária de Cardiologia, Porto Alegre
Faculdade de Medicina Universidade Federal de Pelotas, Pelotas
Hospital do Coração, São Paulo
Faculdade de Medicina de Botucatu Universidade Estadual de São Paulo, Botucatu
